EU Clears GSK-Novartis And Mylan-Abbott Deals, With Minor Conditions
This article was originally published in The Pink Sheet Daily
Executive Summary
Meningitis and tetanus-diphtheria vaccines and smoking cessation products will be divested by GSK in Europe, and B-Raf and MEK inhibitors by Novartis, while Mylan will divest four generics in five markets.